IN2014DN05787A - - Google Patents

Download PDF

Info

Publication number
IN2014DN05787A
IN2014DN05787A IN5787DEN2014A IN2014DN05787A IN 2014DN05787 A IN2014DN05787 A IN 2014DN05787A IN 5787DEN2014 A IN5787DEN2014 A IN 5787DEN2014A IN 2014DN05787 A IN2014DN05787 A IN 2014DN05787A
Authority
IN
India
Prior art keywords
angiotensin
pharmaceutically acceptable
composition
disulfanediylbis
aminobutane
Prior art date
Application number
Other languages
English (en)
Inventor
Cortes Catherine Llorens
Yannick Marc
Desliens Ji Gao
Fabrice Balavoine
Lionel Segard
Original Assignee
Quantum Genomics
Inserm Inst Nat De La Santé Et De La Rech Médicale
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Quantum Genomics, Inserm Inst Nat De La Santé Et De La Rech Médicale filed Critical Quantum Genomics
Publication of IN2014DN05787A publication Critical patent/IN2014DN05787A/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/21Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/255Esters, e.g. nitroglycerine, selenocyanates of sulfoxy acids or sulfur analogues thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/401Proline; Derivatives thereof, e.g. captopril
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41641,3-Diazoles
    • A61K31/41781,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41641,3-Diazoles
    • A61K31/41841,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/47042-Quinolinones, e.g. carbostyril
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/567Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66Microorganisms or materials therefrom
    • A61K35/74Bacteria
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/005Enzyme inhibitors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05Dipeptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0087Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Emergency Medicine (AREA)
  • Mycology (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
IN5787DEN2014 2011-12-21 2012-12-21 IN2014DN05787A (enExample)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP11306735 2011-12-21
PCT/EP2012/076607 WO2013092984A1 (en) 2011-12-21 2012-12-21 Combination of (3s,3s') 4,4'-disulfanediylbis(3-aminobutane 1-sulfonic acid) and a second antihypertensive agent

Publications (1)

Publication Number Publication Date
IN2014DN05787A true IN2014DN05787A (enExample) 2015-05-15

Family

ID=47522577

Family Applications (1)

Application Number Title Priority Date Filing Date
IN5787DEN2014 IN2014DN05787A (enExample) 2011-12-21 2012-12-21

Country Status (25)

Country Link
US (1) US10959938B2 (enExample)
EP (1) EP2793878B1 (enExample)
JP (2) JP6212500B2 (enExample)
KR (1) KR20140116879A (enExample)
CN (2) CN104220062B (enExample)
AU (1) AU2012356895B2 (enExample)
BR (1) BR112014015276B1 (enExample)
CA (1) CA2859704C (enExample)
CY (1) CY1118711T1 (enExample)
DK (1) DK2793878T3 (enExample)
EA (1) EA028718B1 (enExample)
ES (1) ES2619027T3 (enExample)
HR (1) HRP20170267T1 (enExample)
HU (1) HUE033403T2 (enExample)
IL (1) IL233156B (enExample)
IN (1) IN2014DN05787A (enExample)
LT (1) LT2793878T (enExample)
MX (1) MX345469B (enExample)
PL (1) PL2793878T3 (enExample)
PT (1) PT2793878T (enExample)
RS (1) RS55774B1 (enExample)
SI (1) SI2793878T1 (enExample)
SM (1) SMT201700156T1 (enExample)
WO (1) WO2013092984A1 (enExample)
ZA (1) ZA201405266B (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE033403T2 (en) * 2011-12-21 2017-11-28 Quantum Genomics Combination with (3S, 3S ') - 4,4'-disulfandyl-bis (3-aminobutane-1-sulfonic acid) and a second antihypertensive agent
TW202207917A (zh) * 2020-05-06 2022-03-01 法商量子基因科技有限公司 包含腦胺肽酶抑制劑、利尿劑及全身性腎素-血管收縮素系統阻斷劑之醫藥組合物

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2773712B1 (fr) * 1998-01-16 2000-06-02 Inst Nat Sante Rech Med Composition pharmaceutique comprenant au moins un inhibiteur de l'aminopeptidase a
AU2003271811A1 (en) * 2002-07-16 2004-02-02 Institut National De La Sante Et De La Recherche Medicale (Inserm) Novel derivatives of 4,4'-dithiobis-(3-aminobutane-1-sulphonates) and compositions containing same
FR2858617A1 (fr) * 2003-08-06 2005-02-11 Inst Nat Sante Rech Med Derives de 4',4'-dithiobis-(3-aminobutane-1-sulfonate-1- sulfonates) nouveaux et compositions les contenant
US20080014187A1 (en) * 2006-07-15 2008-01-17 Bryant Villeponteau Compositions and Methods for Treating Hypertension and Inflammation
HUE033403T2 (en) * 2011-12-21 2017-11-28 Quantum Genomics Combination with (3S, 3S ') - 4,4'-disulfandyl-bis (3-aminobutane-1-sulfonic acid) and a second antihypertensive agent

Also Published As

Publication number Publication date
CN109464432A (zh) 2019-03-15
PT2793878T (pt) 2017-03-23
BR112014015276A8 (pt) 2017-06-13
MX2014007547A (es) 2014-08-01
CA2859704A1 (en) 2013-06-27
NZ627251A (en) 2015-08-28
BR112014015276B1 (pt) 2020-09-29
EA201400724A1 (ru) 2014-09-30
CY1118711T1 (el) 2017-07-12
US10959938B2 (en) 2021-03-30
JP6726138B2 (ja) 2020-07-22
HUE033403T2 (en) 2017-11-28
JP2017222696A (ja) 2017-12-21
ES2619027T3 (es) 2017-06-22
RS55774B1 (sr) 2017-07-31
LT2793878T (lt) 2017-05-25
MX345469B (es) 2017-02-01
PL2793878T3 (pl) 2017-08-31
AU2012356895A1 (en) 2014-07-31
HK1203051A1 (en) 2015-10-16
BR112014015276A2 (pt) 2017-06-13
DK2793878T3 (en) 2017-03-27
CN104220062B (zh) 2018-06-15
SMT201700156T1 (it) 2017-05-08
IL233156A0 (en) 2014-07-31
JP6212500B2 (ja) 2017-10-11
WO2013092984A1 (en) 2013-06-27
EP2793878B1 (en) 2017-02-01
HRP20170267T1 (hr) 2017-05-19
ZA201405266B (en) 2016-06-29
AU2012356895B2 (en) 2017-05-25
JP2015506338A (ja) 2015-03-02
CA2859704C (en) 2020-04-28
KR20140116879A (ko) 2014-10-06
SI2793878T1 (sl) 2017-07-31
EA028718B1 (ru) 2017-12-29
IL233156B (en) 2018-05-31
US20150320703A1 (en) 2015-11-12
CN104220062A (zh) 2014-12-17
EP2793878A1 (en) 2014-10-29

Similar Documents

Publication Publication Date Title
EA201101672A1 (ru) Замещенные производные аминомасляной кислоты в качестве ингибиторов неприлизина
EA201100691A1 (ru) Антагонисты рецепторов лизофосфатидной кислоты
WO2009088414A3 (en) Oral pharmaceutical dosage forms
MX2013005533A (es) Derivados de acido amino-bisfenil-pentanoico sustituidos como inhibidores de nep.
EA201270467A1 (ru) Полициклические соединения в качестве антагонистов рецепторов лизофосфатидной кислоты
WO2016004093A3 (en) Therapeutic compositions including galectin-3 inhibitors and uses thereof
MX2011011428A (es) Derivados de acido sulfamoilbenzoico como antagonistas de trpm8.
WO2011041729A3 (en) Compounds as lysophosphatidic acid receptor antagonists
WO2011017350A3 (en) Compounds as lysophosphatidic acid receptor antagonists
EA201390821A1 (ru) Антагонисты рецепторов лизофосфатидной кислоты и их применение
HK1215934A1 (zh) 肽治疗剂及其使用方法
NO20073959L (no) Kinazolinderivat, fremgangsmate for fremstilling og anvendelse derav for inhibering av vekst av kreftceller
WO2010141761A3 (en) Polycyclic antagonists of lysophosphatidic acid receptors
EP3626253A3 (en) Stable formulations of linaclotide
WO2010049449A3 (en) Novel salts of sunitinib
WO2008129501A3 (en) Pharmaceutical compositions of duloxetine
FR2906140B1 (fr) Forme galenique pour l'administration par voie trans-muqueuse de principes actifs
MX2012013872A (es) Formas de dosificacion oral de bendamustina.
TN2014000060A1 (en) Benzothiazolone compound
WO2012085249A3 (en) Homogenous pharmaceutical oral dosage forms comprising lercanidipine and enalapril or their pharmaceutically acceptable salts together with an organic acid
WO2007110765A3 (en) Processes for the preparation of octreotide
IN2014DN05787A (enExample)
SG10201809506TA (en) Pharmaceutical compositions comprising 7-(1h-imidazol-4-ylmethyl)-5,6,7,8-tetrahydro-quinoline for treating skin diseases and conditions
TR201803451T4 (tr) Olmesartan formülasyonlari.
PH12012502198A1 (en) Association of xanthine oxidase inhibitors and angiotensin ii receptor antagonists and use thereof